Rhythm Pharmaceuticals Announces European Commission Authorization of IMCIVREE® (setmelanotide)▼ for the Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency
First-ever authorized treatment option in the European Union for these rare genetic diseases of obesityBOSTON, July 23, 2021 (GLOBE NEWSWIRE)...